Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with Addison's disease (AD) report impaired subjective health status (SHS). Since cortisol exhibits a robust circadian cycle that entrains other biological clocks, impaired SHS may be due to the noncircadian cortisol profile achieved with conventional glucocorticoid replacement. Continuous subcutaneous hydrocortisone infusion (CSHI) reproduces a circadian cortisol profile, but its effects on SHS have not been objectively evaluated.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Clin. Endocrinol. Metab.

Title: The Journal of clinical endocrinology and metabolism

ISSN (Electronic): 1945-7197

ISSN (Print): 0021-972X

Publication date (Electronic): Nov 2014

Volume: 99

Issue: 11

Affiliations

[1 ] Endocrine and Metabolic Unit (L.G., M.A.N., T.R.J.T., D.J.T.), Royal Adelaide Hospital, Adelaide 5000, Australia; School of Medicine (L.G., M.A.N., D.J.T.), University of Adelaide 5000, Australia; Diabetes Centre (J.v.d.B.), Royal Adelaide Hospital, Adelaide 5000, Australia; Department of Chemical Pathology (W.A.R.), SA Pathology, Adelaide 5000, Australia; Department of Endocrinology and Diabetes (D.E.H.), Sir Charles Gairdner Hospital, Perth 6009, Australia; School of Medicine and Pharmacology (D.E.H.), University of Western Australia, Perth 6009, Australia; Department of Diabetes and Endocrinology (J.S., W.J.I.), Princess Alexandra Hospital, Brisbane 4102, Australia; and School of Medicine (W.J.I.), University of Queensland, Brisbane 4072, Australia.

Article

DOI: 10.1210/jc.2014-2433

PubMed ID: 25127090

SO-VID: e26c1fc3-241d-4921-8367-86c082616711

History

Data availability:

Comments

Comment on this article

Cited by 22

See all cited by